AFFORDABLE CANCER DRUGS
New health emergency in Canada? Inflammatory Bowel Disease cases skyrocket, according to a global study
A new study reveals a concerning health trend for Canada. Inflammatory Bowel Disease or IBD cases are projected to rise significantly. By the 2030s, over 400,000 Canadians may live with IBD. This surge will challenge the healthcare system. Doctors Gilaad Kaplan and Siew Ng suggest focusing on prevention and better care.
Big development in medical science: This cheap and the most popular diabetes drug used worldwide could help fight colon cancer
Researchers are exploring metformin, a common diabetes drug, as a potential aid in colon cancer treatment. Early studies suggest it could enhance existing therapies, especially for aggressive cancers with mutated KRAS gene. Its affordability and established safety profile make it a promising option, though further animal testing is needed before human trials can commence.
Will the Supreme Court limit free Cancer screenings and preventive drugs under Obamacare? Who has challenged the ACA and why?
As the justices prepare to hear arguments, the stakes remain high, not only for cancer screening and cholesterol medication access, but for the broader structure of government-mandated healthcare coverage in the U.S.
Trump’s executive order on drug pricing could be a booster for Indian pharma industry
Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generic imports. While the move aims to lower drug costs for Americans, potential tariffs on pharma imports create uncertainty.
People living by river drains more prone to cancer: ICMR cites study
A 2024 study found that individuals living near river drains are at a high risk of cancer. The Indian government has approved various initiatives, including the establishment of cancer institutes and offering affordable medicines, to combat this issue and provide comprehensive cancer care across the country.
Govt reviewing infrastructure of district hospitals for setting up daycare cancer centres
The government has initiated a survey to review infrastructure in district hospitals for establishing daycare cancer centres over the next three years, with an estimated expenditure of Rs 3,200 crore. The initiative aims to improve access to quality cancer care, especially in rural areas, and reduce the burden on tertiary-care centres.
- Go To Page 1
Over 3k brands hit pharma mkt, cancer drug tops in sales
India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the top-seller, reflecting a rise in cancer cases. Enhertu, exempted from customs duty, has significantly contributed to AstraZeneca's sales, highlighting the growing demand for innovative cancer treatments.
Biocon urges government to exempt cancer, rare-disease drugs from tax in budget
India should eliminate tax on drugs for cancer treatment and chronic diseases, urged Biocon's chairperson Kiran Mazumdar-Shaw, ahead of the budget. She highlighted the heavy financial burden on patients and called for making lifesaving therapies affordable by removing taxes and cutting import duties on medical equipment.
Med in India: Quality, affordability, access
Drugs made locally, be it under patent or generic, must be of high and uniform quality. Variations in quality has dogged the domestic pharma sector. Uneven quality of medicines will undermine the Jan Aushadhi scheme geared to making prescription drugs affordable, even as GoI has more than doubled its spend on it. The drug regulatory structure must be overhauled for greater accountability and transparency
Price cuts to hit quality of cancer care: HCG CEO
HCG has filed a writ petition with the Karnataka High Court challenging the decision of the National Pharmaceutical Pricing Control.
MSD launches blockbuster cancer drug Keytruda in India
DCGI gave MSD permission to market Keytruda in June 2016, according to minutes of the regulator’s Subject Expert Committee on oncology and haematology.
Big boost for Biocon as USFDA Onco committee approves company's first breast cancer biosimilar drug
The USFDA's Oncology Drugs Advisory Committee voted 16-0 in support of the eligible indications of the original product.
Biosimilar drugs are priced too high and do little to improve accessibility: Doctors
Biosimilar drugs are follow-on biologics that have nearly the same efficacy as the original drug and used to treat cancer or autoimmune diseases like rheumatoid arthritis.
Drugs for BP, cancer among 54 to see up to 55% price cut
The move is aimed at bringing down prices of commonly used drugs for critical diseases by expanding span of price regulation to cover new drugs, NPPA Chairman Bhupinder Singh said.
Swiss drugmaker Roche launches costliest cancer drugs in India
Kadcyla and Perjeta, the new class of drugs launched in India in October, cost Rs 2,10,000 (200 ml) and Rs 2,49,000 for a dosage, respectively.
NPPA invites comments on Tata Memorial list of cancer drugs
"(this is) on revision of NLEM 2011 with respect to addition/ deletion of drugs relating to oncology from price control and affordability angle."
After BMS's patent rights for Dasatinib, expensive drugs should be brought under price control
India's patent laws are mostly in sync with global rules. However, a clutch of pharma companies including BMS has challenged the enforcement of these laws.
Eli Lilly enters branded generics; launches four cancer drugs
Drug firm Eli Lilly and Company India today said it has entered into branded generics segment in the country with the launch of four cancer drugs.
Cadila Pharmaceuticals launches lung cancer drug
The company claims that the drug Mycidac-C is for the first time in the world an affordable, unique and innovative drug for the treatment of lung cancer.
Policy lethargy must end to hold drug prices down
A superior option is for the government to impose price controls on expensive drugs, whether imported or produced domestically.
Japan's Eisai to launch breast cancer drug in India
Japan's Eisai Pharma is slated to launch in India its novel anti-cancer drug Eribulin, sold under the brand name of Halaven.
Cancer medicines for as low as Rs 1,000 a month on way
Tata Memorial Hospital’s doctors are working on alternatives that could cost less than Rs 1,000 a month.
Doctors call for reduction in cancer drug prices
Advocating for lower drug prices is a necessity to save the lives of patients who cannot afford them,” said a research report backed by the group of oncologists from across the world.
Will continue selling Nexavar drug post IPAB verdict: Bhaskar Narayana, Natco Pharma
In an interview with ET Now, Bhaskar Narayana, Finance-Director, Natco Pharma, talks about the IPAB’s verdict on Natco’s cancer drug case against Bayer AG.
Bayer petition against Natco over manufacture of Nexavar dismissed
Intellectual Property Appellate Board of Chennai dismissed Bayer's plea, seeking a stay on Compulsory License issued to Natco to make Nexavar.
Govt looks to source cancer drugs at a discount from cos
The government is in talks with drugmakers for sourcing medicines to treat cancer at a discount to be sold at its low-cost pharmacy chain Jan Aushadhi stores at affordable prices.
Cipla in talks with Centre to share cancer drug know-how
Pharma powerhouse Cipla has started talks with the government to share knowledge on making cancer drugs, which, if successful, could radically lower the prices of a class of medicines that remain largely unaffordable.
Cancer drugs may come under NPPA lens
Cancer drugs may soon come under the purview of India’s drug price regulator, as they have become too expensive for the common man to afford.
HC allows CPAA to join Bayer-Cipla case
The Delhi High Court (HC) has allowed cancer patient group Cancer Patients Aid Association (CPAA) to join the Bayer AG and Cipla case.
Load More
